paclitaxel + nedaplatin + Endostar

A combination therapy consisting of paclitaxel (a taxoid chemotherapeutic agent), nedaplatin (a platinum-based chemotherapy drug), and Endostar (recombinant human endostatin). This regimen works through multiple mechanisms: 1. **Paclitaxel** interferes with microtubule function by hyper-stabilizing their structure, preventing cell division. It binds to the β subunit of tubulin, locking these building blocks in place and preventing microtubule disassembly, which is necessary for cell function. This disrupts mitosis and induces programmed cell death (apoptosis) in cancer cells. 2. **Nedaplatin** is a platinum-based chemotherapy drug similar to cisplatin but with potentially lower toxicity. It works by forming DNA crosslinks that prevent DNA replication and transcription, leading to cell death. 3. **Endostar** (recombinant human endostatin) is an angiogenesis inhibitor that targets tumor vasculature. It inhibits endothelial cell migration and angiogenesis, normalizing abnormal vasculature in tumors and improving delivery of other drugs, enhancing their anti-tumor effect. The combination has shown promising efficacy in treating esophageal squamous cell carcinoma with acceptable toxicity profiles.